XML 71 R15.htm IDEA: XBRL DOCUMENT v2.4.0.8
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Jun. 30, 2014
COMMITMENTS AND CONTINGENCIES [Abstract]  
COMMITMENTS AND CONTINGENCIES
NOTE 7:-COMMITMENTS AND CONTINGENCIES
 
a.
The facilities of the Subsidiary are rented under operating lease agreements, which expire on various dates, the latest of which is in 2017. In January 2013 the Subsidiary received from the lessor a non-refundable payment, which payment represents the lessor participation in the leasehold improvements, of approximately $816. The payment is deductible against lease expenses as it is incurred. The lessor upfront payment is included the in balance sheet as advance payment and recognized as a deduction from lease expenses over the lease term.
 
The Company recognizes rent expense, net of lessor participation, under such arrangements on a straight-line basis over the lease term.
 
As of June 30, 2014 aggregate minimum lease commitments under non-cancelable operating lease agreements are as follows:
 
Year ending June 30,
      
2015
   $ 667  
2016
     497  
2017
     349  
Total
   $ 1,513  
 
Lease expenses amounted to $720, $678 and $382 for the years ended June 30, 2014, 2013 and 2012, respectively.
 
The Subsidiary has issued a bank guarantee in favor of the lessors for $388.
 
b.
The Subsidiary leases several motor vehicles under operating lease agreements, which expire in various dates during years 2014 through April 2017.
 
As of June 30, 2014, future aggregate minimum lease commitments under non-cancelable operating lease agreements are as follows:
 
Year ending June 30,
      
2015
   $ 140  
2016
     85  
2017
     26  
Total
   $ 251  
 
Lease expenses amounted to $244, $215 and $176 for the years ended June 30, 2014, 2013 and 2012, respectively.
 
c.
An amount of $4,805 of cash and deposits was pledged by the Subsidiary to secure the hedging transactions, credit line and Bank guarantees.
 
d.
Under the Law for the Encouragement of Industrial Research and Development, 1984, (the "Research Law"), research and development programs that meet specified criteria and are approved by a governmental committee of the OCS are eligible for grants of up to 50% of the project's expenditures, as determined by the research committee, in exchange for the payment of royalties from the sale of products developed under the program. Regulations under the Research Law generally provide for the payment of royalties to the Chief Scientist of 3% to 4% on sales of products and services derived from a technology developed using these grants until 100% of the dollar-linked grant is repaid. The Company's obligation to pay these royalties is contingent on its actual sale of such products and services. In the absence of such sales, no payment is required. Outstanding balance of the grants will be subject to interest at a rate equal to the 12 month LIBOR applicable to dollar deposits that is published on the first business day of each calendar year. Following the full repayment of the grant, there is no further liability for royalties.
 
Through June 30, 2014, total grants obtained aggregated to approximately $14,125. Through June 30, 2014, total royalties paid and accrued amounted to $53. As of June 30, 2014, the Company's contingent liability in respect to royalties to the OCS amounted $14,072, not include LIBOR interest as described above.